{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:14:24Z","timestamp":1792761264927,"version":"4.5.0"},"reference-count":59,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Sodium glucose cotransporter 2 inhibitors (SGLT2i) block the reabsorption of glucose by inhibiting SGLT2, thus improving glucose control by promoting the renal excretion of glucose, without requiring insulin secretion. This pharmacological property of SGLT2i reduces body weight and improves insulin resistance in diabetic patients. Such beneficial metabolic changes caused by SGLT2i are expected to be useful not only for glucose metabolism, but also for the protection for various organs. Recent randomized controlled trials (RCTs) on cardiovascular diseases (EMPA-REG OUTCOME trial and CANVAS program) showed that SGLT2i prevented cardiovascular death and the development of heart failure. RCTs on renal events (EMPA-REG OUTCOME trial, CANVAS program, and CREDENCE trial) showed that SGLT2i suppressed the progression of kidney disease. Furthermore, SGLT2i effectively lowered the liver fat content, and our study demonstrated that SGLT2i reduced the degree of hepatic fibrosis in patients at high-risk of hepatic fibrosis. Such promising properties of SGLT2i for cardiovascular, renal, and hepatic protection provide us the chance to think about the underlying mechanisms for SGLT2i-induced improvement of multiple organs. SGLT2i have various mechanisms for organ protection beyond glucose-lowering effects, such as an increase in fatty acids utilization for hepatic protection, osmotic diuresis for cardiac protection, an improvement of insulin resistance for anti-atherogenesis, and an improvement of tubuloglomerular feedback for renal protection.<\/jats:p>","DOI":"10.3390\/ijms22094416","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T12:08:30Z","timestamp":1619179710000},"page":"4416","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors"],"prefix":"10.3390","volume":"22","author":[{"given":"Hidekatsu","family":"Yanai","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Chiba 272-8516, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Hakoshima","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Chiba 272-8516, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Chiba 272-8516, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayuki","family":"Katsuyama","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Chiba 272-8516, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1742-1241.2008.01829.x","article-title":"Sodium glucose co-transporter 2 inhibitors: Blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes","volume":"62","author":"Jabbour","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/jocmr2385w","article-title":"Sodium-glucose cotransporter 2 inhibitors: Possible anti-atherosclerotic effects beyond glucose lowering","volume":"8","author":"Yanai","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.14740\/jocmr2467w","article-title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes: A Chart-Based Analysis","volume":"8","author":"Katsuyama","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.14740\/jocmr3046w","article-title":"Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations with Baseline Data","volume":"9","author":"Yanai","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e004007","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/a-0958-2441","article-title":"Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes","volume":"51","author":"Wu","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yanai, H., and Yoshida, H. (2019). Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051190"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12933-019-0826-0","article-title":"Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: The prospective AIRE Study","volume":"18","author":"Sasso","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/ndt\/gfy032","article-title":"Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: Pooled analysis of four cohort studies","volume":"33","author":"Minutolo","year":"2018","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.35772\/ghm.2020.01078","article-title":"Secondary dyslipidemia: Its treatments and association with atherosclerosis","volume":"3","author":"Yanai","year":"2021","journal-title":"Glob. Health Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","article-title":"Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin","volume":"14","author":"Devineni","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14740\/jocmr3676","article-title":"An Effective Insulin Therapy in Combination with Sodium-Glucose Cotransporter 2 Inhibitors","volume":"11","author":"Yanai","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.14740\/jocmr2547w","article-title":"An Influence of the Estimated Glomerular Filtration Rate on Improvement in Metabolic Parameters by Sodium-Glucose Cotransporter 2 Inhibitors","volume":"8","author":"Katsuyama","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.14740\/jocmr3004w","article-title":"What Properties of Sodium-Glucose Cotransporter 2 Inhibitors Determine the Improvement in Hemoglobin A1c and Body Weight?","volume":"9","author":"Yanai","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE\u2013TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"470","DOI":"10.21037\/atm.2017.09.22","article-title":"Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes","volume":"5","author":"Yanai","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.14740\/jocmr2857w","article-title":"A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production","volume":"9","author":"Yanai","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jch.13174","article-title":"Understanding of hypertension and heart failure in patients with type 2 diabetes by studying effects of sodium-glucose cotransporter 2 inhibitors on plasma B-type natriuretic peptide levels","volume":"20","author":"Yanai","year":"2018","journal-title":"J. Clin. Hypertens."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.14740\/jem426w","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure","volume":"7","author":"Yanai","year":"2017","journal-title":"J. Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/jdi.12644","article-title":"Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus","volume":"8","author":"Kashiwagi","year":"2017","journal-title":"J. Diabetes Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"Cv Protection in the Empa-Reg Outcome Trial: A \u201cThrifty Substrate\u201d Hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11936-017-0522-x","article-title":"Promise of Sglt2 Inhibitors in Heart Failure: Diabetes and Beyond","volume":"19","author":"Martens","year":"2017","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the Empa-Reg Outcome Study? A Unifying Hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/phar.1881","article-title":"1SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature","volume":"37","author":"Burke","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.CIR.73.5.913","article-title":"Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure","volume":"73","author":"Leimbach","year":"1986","journal-title":"Circulation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijcard.2008.03.056","article-title":"Increased muscle sympathetic nerve activity predicts mortality in heart failure patients","volume":"135","author":"Barretto","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Joshi, S.S., Singh, T., Newby, D.E., and Singh, J. (2021). Sodium-glucose co-transporter 2 inhibitor therapy: Mechanisms of action in heart failure. Heart.","DOI":"10.1136\/heartjnl-2020-318060"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.14740\/jocmr3220w","article-title":"The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4","volume":"9","author":"Koguchi","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.14740\/jem609","article-title":"Dipeptidyl Peptidase-4 Inhibitor versus Sodium-Glucose Cotransporter-2 Inhibitor in the Management of Type 2 Diabetes","volume":"9","author":"Yanai","year":"2019","journal-title":"J. Endocrinol. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased Hematocrit during Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2009.03.065","article-title":"Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat","volume":"612","author":"Toba","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1159\/000319653","article-title":"Erythropoietin protects podocytes from damage by advanced glycation end-products","volume":"117","author":"Ruester","year":"2011","journal-title":"Nephron Exp. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"F911","DOI":"10.1152\/ajprenal.00643.2012","article-title":"Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db\/db mouse","volume":"305","author":"Loeffler","year":"2013","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Wie","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","article-title":"Adenosine and kidney function","volume":"86","author":"Vallon","year":"2006","journal-title":"Physiol. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"769","DOI":"10.14740\/jocmr4019","article-title":"The Possible Mechanisms for Improvement of Liver Function due to Sodium-Glucose Cotransporter-2 Inhibitors","volume":"11","author":"Yanai","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/Glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0065-2571(98)00016-8","article-title":"The regulation of acetyl-CoA carboxylase--a potential target for the action of hypolipidemic agents","volume":"39","author":"Munday","year":"1999","journal-title":"Adv. Enzyme Regul."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bph.14859","article-title":"Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and nonalcoholic fatty liver disease in mice","volume":"177","author":"Chiang","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1210\/en.2015-1588","article-title":"Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice","volume":"157","author":"Obata","year":"2016","journal-title":"Endocrinology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(63)91500-9","article-title":"The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus","volume":"1","author":"Randle","year":"1963","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/jem632","article-title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Hepatic Fibrosis in Patients with Type 2 Diabetes: A Chart-Based Analysis","volume":"10","author":"Katsuyama","year":"2020","journal-title":"J. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Sumida, Y., Yoneda, M., Hyogo, H., Itoh, Y., Ono, M., Fujii, H., Eguchi, Y., Suzuki, Y., Aoki, N., and Kanemasa, K. (2012). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol., 12.","DOI":"10.1186\/1471-230X-12-2"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/0026-0495(95)90135-3","article-title":"Regulation of hormone-sensitive lipase in streptozotocin-induced diabetic rats","volume":"44","author":"Sztalryd","year":"1995","journal-title":"Metabolism"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/4416\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:51:50Z","timestamp":1760161910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/4416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":59,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["ijms22094416"],"URL":"https:\/\/doi.org\/10.3390\/ijms22094416","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]}}}